Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)

SHE:002773 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	3,422	6,435	5,690	4,702	3,585	2,939
Trading Asset Securities	2,919	-	-	-	100	200
Cash & Short-Term Investments	6,341	6,435	5,690	4,702	3,685	3,139
Cash Growth	5.71%	13.11%	21.00%	27.59%	17.41%	-5.67%
Accounts Receivable	288.12	189.1	177.85	160.41	160.69	204.63
Other Receivables	46.68	37.31	21.67	19.04	27.88	43.59
Receivables	334.8	226.4	199.52	179.45	188.57	248.22
Inventory	405.2	407.05	386.86	403.61	330.96	295.62
Prepaid Expenses	0	1.64	-	-	-	-
Other Current Assets	73	13.93	12.93	20.41	24.22	15.89
Total Current Assets	7,154	7,084	6,289	5,306	4,229	3,699
Property, Plant & Equipment	2,179	2,253	2,353	2,411	2,553	2,097
Long-Term Investments	15.38	15.79	16.44	16.78	16.98	17.73
Other Intangible Assets	341.22	352.93	286.89	316.8	331.14	278.21
Long-Term Deferred Tax Assets	103.02	128.85	259.46	358.08	486.31	545.66
Long-Term Deferred Charges	133.7	61.76	123.24	99.33	70.47	84.67
Other Long-Term Assets	12.68	23.07	14.48	22.01	33.93	233.89
Total Assets	9,939	9,920	9,342	8,530	7,721	6,956

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	189.76	221.43	297.16	344.03	409.54	343.13
Accrued Expenses	273.55	189.45	233.88	203.64	169.59	174.63
Current Portion of Leases	1.55	1.68	1.73	0.53	1.6	2.57
Current Income Taxes Payable	32.25	18.04	13.31	9.82	19.69	16.49
Current Unearned Revenue	9.33	2.06	8.92	5.1	9.14	8.39
Other Current Liabilities	206.55	169.05	99.98	91.31	84.1	122.16
Total Current Liabilities	712.99	601.72	654.99	654.43	693.66	667.37
Long-Term Leases	0.6	1.82	3.47	1.48	3.27	4.43
Long-Term Unearned Revenue	34.05	32.1	23.58	22.94	30.3	25.51
Long-Term Deferred Tax Liabilities	10.66	9.58	13.03	7.94	5.14	2.06
Other Long-Term Liabilities	-	-	-	30.96	81.48	151.71
Total Liabilities	758.3	645.22	695.07	717.76	813.85	851.08

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	921.33	921.32	919.78	919.46	919.46	919.46
Additional Paid-In Capital	2,028	2,031	1,997	1,990	1,994	1,986
Retained Earnings	6,268	6,348	5,738	4,896	3,989	3,185
Comprehensive Income & Other	-3.15	-1.45	-1.33	-1.34	-1.05	-0.83
Total Common Equity	9,215	9,299	8,653	7,804	6,902	6,090
Minority Interest	-34.07	-24.27	-6.34	7.89	5.07	15.24
Shareholders' Equity	9,181	9,275	8,647	7,812	6,907	6,105
Total Liabilities & Equity	9,939	9,920	9,342	8,530	7,721	6,956

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	2.15	3.51	5.2	2.01	4.87	7
Net Cash (Debt)	6,339	6,432	5,684	4,700	3,681	3,132
Net Cash Growth	5.74%	13.15%	20.94%	27.70%	17.52%	-5.88%
Net Cash Per Share	6.86	6.97	6.20	5.13	4.02	3.42
Filing Date Shares Outstanding	921.33	921.32	919.78	919.46	919.46	919.46
Total Common Shares Outstanding	921.33	921.32	919.78	919.46	919.46	919.46
Working Capital	6,441	6,483	5,634	4,651	3,535	3,031
Book Value Per Share	10.00	10.09	9.41	8.49	7.51	6.62
Tangible Book Value	8,874	8,946	8,366	7,487	6,571	5,812
Tangible Book Value Per Share	9.63	9.71	9.10	8.14	7.15	6.32
Buildings	2,150	2,111	2,126	1,989	1,785	1,137
Machinery	1,437	1,387	1,271	1,236	1,088	830.91
Construction In Progress	29.13	97.56	112.35	166.54	475.88	808.69

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error